关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
$ Y8 C+ f( k7 q' V1 f8 m    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
$ L3 }% v3 T/ P9 s4 T5 }: I; U; `
4 y: R# d  ]/ ?, x9 u" G作者：来自澳大利亚
5 O0 T, Y7 R" C) S4 ?来源：Haematologica. 2011.8.9.
- {9 V- F+ f+ p% ~: v- g9 U" Z/ iDear Group,
6 c! Y( x* o. y- t, C3 p1 b
Some of you are on Dasatinib (Sprycel) and we wish to give news on all CML
) N0 T! J- `/ I. K) `3 Ztherapies. Here is a report from Australia on 3 patients who went off Sprycel
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
does spike up the immune system so I hope more reports come out on this issue.

1 |( N% `9 Y- wThe remarkable news about Sprycel cessation is that all 3 patients had failed
7 Y) \9 S' _4 X* z( M* EGleevec and Sprycel was their second TKI so they had resistant disease. This is
- F: E* c# l  _# U% c2 Odifferent from the stopping Gleevec trial in France which only targets patients
who have done well on Gleevec.

Hopefully, the doctors will report on a larger study and long-term to see if the
, T4 o7 N& x; o3 O9 a! L+ Zresponse off Sprycel is sustained.

2 h2 j0 Z# m- c2 u$ VBest Wishes,
; y" ~2 l8 p9 }1 H, ]: e% p6 j4 hAnjana
6 {( t5 [/ y* k# I+ Y7 g+ D
. O) _  h' L& O
/ I* f: H3 o, D6 ^. s
, @2 D! e$ B! x3 AHaematologica. 2011 Aug 9. [Epub ahead of print]
Durable complete molecular remission of chronic myeloid leukemia following
6 ^8 s# Q$ H1 D, d! Odasatinib cessation, despite adverse disease features.
Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
0 r1 v) m+ w  SSource
Adelaide, Australia;

4 ]* T! t0 E5 C. o% nAbstract
" j4 @& m9 V) Y6 D+ jPatients with chronic myeloid leukemia, treated with imatinib, who have a
durable complete molecular response might remain in CMR after stopping
5 E4 `4 Q* C6 u/ v5 m3 ^treatment. Previous reports of patients stopping treatment in complete molecular
( I+ ^& K! P' ]+ @: \) wresponse have included only patients with a good response to imatinib. We
describe three patients with stable complete molecular response on dasatinib
treatment following imatinib failure. Two of the three patients remain in
( _! _! v, L- d: f8 ?, ]1 u) hcomplete molecular response more than 12 months after stopping dasatinib. In
6 u. N. n4 n' b" W" K7 @these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
3 s2 B, ]( S0 @show that the leukemic clone remains detectable, as we have previously shown in
imatinib-treated patients. Dasatinib-associated immunological phenomena, such as
the emergence of clonal T cell populations, were observed both in one patient
& s9 T4 k! `9 \. Q( O; Bwho relapsed and in one patient in remission. Our results suggest that the
# d  Y3 X' [0 W8 l$ h3 Ucharacteristics of complete molecular response on dasatinib treatment may be
% `% V4 \1 `( k: V7 Bsimilar to that achieved with imatinib, at least in patients with adverse
disease features.

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
1 I0 g& R, h% a& p+ F) d5 S* L/ G    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。

作者：来自法国STIM试验
  R" N7 b% |+ ~0 ~5 Q来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事